-
| CurrencyCode | USD |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | PINK |
| ISIN | US09076G4010 |
| Market Cap | 4M |
|---|---|
| PE Ratio | None |
| Target Price | 15 |
| Beta | 0.29 |
| Dividend Yield | None |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BPTSY using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026